《2025年代谢功能障碍相关脂肪性肝病和脂肪性肝炎全球共识建议摘译

打开文本图片集

关键词：代谢相关脂肪性肝病；代谢相关脂肪性肝炎；诊疗准则基金项目：南昌大学第二附属医院博士启动基金（B2273）；北京肝胆相照公益基金会临床科研专项资助基金（iGandanF-1082024-LG009）；北京肝胆相照公益基金会人工肝专项基金（RGGJJ-2021-028）

An excerpt of global consensus recommendations for metabolicdysfunction-associated steatotic liver disease and steatohepatitis （2025）

LIU Aifang'， ZOU BoI ，LUO Lei’， ZHANG Jing²，YANG Wenlongl

1.Departmentof InfectiousDiseases，TheSecond Afliated Hospitalof Nanchang University，Nanchang 33oo6，China;

2.DiagnosisndeatmntCenterofattLDisese，eijinYonHospal，apaldicalUiersityeijino9in

Coresponding authors：LUOLei，Zgl1990@163.com（ORCID：000-002-7999-9560）；ZHANG Jing，zjyouan@ccmu.edu.cn （ORCID： 0000-0002-3082-8330）; YANG Wenlong，wenl0oyang@163.com （ORCID： 0000-0003-3756-7468）

Abstract：InApril2O25，Globalconsensusrecommendationsformetabolicdysfunction-asociatedsteatotic liverdiseaseand steatohepatitiswaspublishedonlineinGastroenterolog.Theserecommendationsaddress theareaswithsignificantdivergence，such as metabolicdysfunction-assciated steatotic liver disease（MASLD）screening steps，theuseof noninvasive tests forrisk stratification，managementofcomorbidities，andtherecentadvances inresmetiromforthetreatmentof metabolicdysfunctionassociated steatohepatis（MASH），covering themostdebated topics incurent MASLD management.Thisarticle makesan excerpt of the main contents in these consensus recommendations.

KeyWords：MetabolicDysfunction-AssociatedSteatoticLiverDisease；MetabolicDysfunction-Asociated Steatohepatitis; Practice Guideline

Researchfunding：PHD StartupFundofthe SecondAfiliatedHospitalofNanchang University（B2273）；Beijing iGandan Foundation ClinicalResearch SpecialFund（iGandanF-1082024-LGo09）；Beijing iGandan FoundationArtificialLiverSpecial Fund （RGGJJ-2021-028）

代谢功能障碍相关脂肪性肝病（metabolicdysfunction-associatedsteatoticliverdisease，MASLD）及其严重亚型代谢功能障碍相关脂肪性肝炎（metabolicdysfunction-associatedsteatohepatitis，MASH）是全球最常见的慢性肝病之一，可进展为肝硬化、肝细胞癌（HCC），影响全球约三分之一的成年人口，发病年龄逐渐年轻化。（剩余4082字）